๐ COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?
A severe outbreak of coronavirus disease 2019 (COVID-19) emerged in China in December 2019, and spread so rapidly that more than 200,000 cases have so far been reported worldwide; on January 30, 2020, the WHO declared it the sixth public health emergency of international concern. The two previously reported coronavirus epidemics (severe acute respiratory syndrome [SARS] and Middle East respiratory syndrome [MERS]) share similar pathogenetic, epidemiological and clinical features as COVID-19. As little is currently known about SARS-CoV-2, it is likely that lessons learned from these major epidemics can be applied to the new pandemic, including the use of novel immunosuppressive drugs.
keywords
๐ severe acute (1373)
๐ public health (392)
๐ international concern (28)
๐ respiratory syndrome (2004)
๐ acute respiratory (1734)
๐ previously reported (79)
author
๐ค Sarzi-Puttini, Piercarlo
๐ค Giorgi, Valeria
๐ค Sirotti, Silvia
๐ค Marotto, Daniela
๐ค Ardizzone, Sandro
๐ค Rizzardini, Giuliano
๐ค Antinori, Spinello
๐ค Galli, Massimo
year
โฐ 2020
journal
๐ Clin Exp Rheumatol
issn
๐
volume
number
page
doi
๐ โคด
citedbycount
0
download
๐ [BibTeX]